Cargando…

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haugh, Isabel M, Preston, Allie K, Kivelevitch, Dario N, Menter, Alan M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237136/ https://www.ncbi.nlm.nih.gov/pubmed/30518998 http://dx.doi.org/10.2147/DDDT.S167149

Ejemplares similares

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019)

Risankizumab for psoriasis
Publicado: (2020)

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
por: Menter, Alan, et al.
Publicado: (2021)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes, Katie E, et al.
Publicado: (2016)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
por: Al Muqrin, Abdullah Muqrin, et al.
Publicado: (2022)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
por: Barber, Cara, et al.
Publicado: (2022)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
por: Suleiman, Ahmed A., et al.
Publicado: (2018)

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2021)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
por: Yu, Qianying, et al.
Publicado: (2022)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
por: Gracia-Cazaña, Tamara, et al.
Publicado: (2023)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2eve86kr6re281b9iuog2ri095